lurbinectedin + atezolizumab

**Lurbinectedin + atezolizumab** is a combination regimen under regulatory review as a first-line maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction chemotherapy with atezolizumab, carboplatin, and etoposide. Lurbinectedin is a selective inhibitor of oncogenic transcription and an alkylating agent that exerts anticancer effects by binding DNA, blocking RNA polymerase II, leading to DNA damage, cell cycle arrest, apoptosis, modulation of the tumor microenvironment, and immunogenic cell death. Atezolizumab is a monoclonal antibody targeting PD-L1, acting as an immune checkpoint inhibitor to enhance T cell–mediated antitumor immunity. In the Phase 3 IMforte trial, this combination demonstrated statistically significant improvements in both progression-free survival and overall survival compared to atezolizumab alone, with a favorable and manageable safety profile[1][2][3][4][7][8][5]. Lurbinectedin is marketed as Zepzelca by Jazz Pharmaceuticals; atezolizumab is marketed as Tecentriq by Roche.

Brand names

Zepzelca + Tecentriq

Other names

PM 01183 + atezolizumabPM01183 + atezolizumablurbinectedin + MPDL3280A